Overview

Phase II Study of Lenalidomide for the Treatment of Relapsed or Refractory Hodgkin's Lymphoma

Status:
Completed
Trial end date:
2014-06-01
Target enrollment:
Participant gender:
Summary
This is a single-arm, open-label Phase II study evaluating the activity of Lenalidomide in patients with relapsed or refractory Hodgkin's lymphoma.
Phase:
Phase 2
Details
Lead Sponsor:
University Health Network, Toronto
Collaborator:
Celgene Corporation
Treatments:
Lenalidomide
Thalidomide